Skip to main content
Top
Published in: Acta Diabetologica 4/2014

01-08-2014 | Original Article

Duration of diabetes and effectiveness of insulin in the management of insulin-naïve Korean patients uncontrolled on oral antidiabetic drugs: a sub-analysis of the MOdaliTy of Insulin treatment eValuation (MOTIV) registry results

Authors: Sang Soo Kim, In Joo Kim, Yong Ki Kim, Kun Ho Yoon, Ho Young Son, Sung Woo Park, Yeon Ah Sung, Hong Sun Baek, Kyoung Soo Ha

Published in: Acta Diabetologica | Issue 4/2014

Login to get access

Abstract

To investigate whether duration of diabetes has an impact on the effectiveness of insulinization in diabetes management. This open-label, noninterventional, observational registry was conducted at >500 centers in Korea. Patients with diabetes, on oral antidiabetic drugs, with HbA1c ≥7 % (53 mmol/mol) in the preceding 3 months, being considered for initiation of basal insulin by their physicians, were included. Data were collected at baseline and at 3 and 6 months. Of 6,616 patients evaluated, 62.5 % had diabetes for <10 years, while only 6.5 % patients had diabetes for ≥20 years. At the end of study, average HbA1c in patients with diabetes for <10 years, for 10 to <20 years, and for ≥20 years was 7.3 ± 1.0 % (56 ± 10.9 mmol/mol), 7.4 ± 1.0 % (57 ± 10.9 mmol/mol), and 7.6 ± 1.1 % (60 ± 12.0 mmol/mol), respectively. Over half the patients (50.7 %) with diabetes <10 years achieved HbA1c <7 % (53 mmol/mol) by the end of study, while only 42.1 and 35.1 % patients with diabetes for 10 to <20 and ≥20 years, respectively, achieved their target. The average insulin dosage required for per unit HbA1c reduction was significantly different among the groups according to duration of type 2 diabetes mellitus (p < 0.05). Among patients who achieved HbA1c <7 %, proportion of patients with hypoglycemia in the ≥20 years group was higher than that in the <10 years, 10 to <20 years groups. Early insulin administration provided a better glycemic control with less insulin dosage and lower frequency of hypoglycemic events. Thus, early insulinization might hold the key to better management of type 2 diabetes mellitus.
Literature
4.
go back to reference Lim S, Kim DJ, Jeong IK et al (2009) A nationwide survey about the current status of glycemic control and complications in diabetic patients in 2006: the committee of the Korean diabetes association on the epidemiology of diabetes mellitus. Korean Diabetes J 33:48–57CrossRef Lim S, Kim DJ, Jeong IK et al (2009) A nationwide survey about the current status of glycemic control and complications in diabetic patients in 2006: the committee of the Korean diabetes association on the epidemiology of diabetes mellitus. Korean Diabetes J 33:48–57CrossRef
5.
go back to reference Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379PubMedCentralPubMedCrossRef Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379PubMedCentralPubMedCrossRef
6.
go back to reference Jabbour S (2008) Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both? Int J Clin Pract 62:845–847PubMedCrossRef Jabbour S (2008) Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both? Int J Clin Pract 62:845–847PubMedCrossRef
7.
go back to reference Riedel AA, Heien H, Wogen J, Plauschinat CA (2007) Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. Am J Manag Care 13:457–463PubMed Riedel AA, Heien H, Wogen J, Plauschinat CA (2007) Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. Am J Manag Care 13:457–463PubMed
8.
go back to reference Riedel AA, Heien H, Wogen J, Plauschinat CA (2007) Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 27:1102–1110PubMedCrossRef Riedel AA, Heien H, Wogen J, Plauschinat CA (2007) Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 27:1102–1110PubMedCrossRef
9.
go back to reference Brown JB, Nichols GA, Perry A (2004) The burden of treatment failure in type 2 diabetes. Diabetes Care 27:1535–1540PubMedCrossRef Brown JB, Nichols GA, Perry A (2004) The burden of treatment failure in type 2 diabetes. Diabetes Care 27:1535–1540PubMedCrossRef
10.
go back to reference Vinik A (2007) Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther 29:1236–1253CrossRef Vinik A (2007) Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther 29:1236–1253CrossRef
12.
go back to reference Tsai ST, Pathan F, Ji L et al (2011) First insulinization with basal insulin in patients with type 2 diabetes in a real-world setting in Asia. J Diabetes 3:208–216PubMedCentralPubMedCrossRef Tsai ST, Pathan F, Ji L et al (2011) First insulinization with basal insulin in patients with type 2 diabetes in a real-world setting in Asia. J Diabetes 3:208–216PubMedCentralPubMedCrossRef
13.
go back to reference Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, ATLANTUS Study Group (2005) Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28:1282–1288PubMedCrossRef Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, ATLANTUS Study Group (2005) Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28:1282–1288PubMedCrossRef
14.
go back to reference Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080–3086PubMedCrossRef Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080–3086PubMedCrossRef
15.
16.
go back to reference Davidson MB (2005) Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care 28:222–224PubMedCrossRef Davidson MB (2005) Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care 28:222–224PubMedCrossRef
17.
go back to reference Home PD, Boulton AJM, Jimenez J, Landgraf R, Osterbrink B, Christiansen JS (2003) Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diabetes Int 20:63–71CrossRef Home PD, Boulton AJM, Jimenez J, Landgraf R, Osterbrink B, Christiansen JS (2003) Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diabetes Int 20:63–71CrossRef
18.
go back to reference Peyrot M, Rubin RR, Lauritzen T et al (2005) Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care 28:2673–2679PubMedCrossRef Peyrot M, Rubin RR, Lauritzen T et al (2005) Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care 28:2673–2679PubMedCrossRef
19.
go back to reference ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328PubMedCrossRef ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328PubMedCrossRef
Metadata
Title
Duration of diabetes and effectiveness of insulin in the management of insulin-naïve Korean patients uncontrolled on oral antidiabetic drugs: a sub-analysis of the MOdaliTy of Insulin treatment eValuation (MOTIV) registry results
Authors
Sang Soo Kim
In Joo Kim
Yong Ki Kim
Kun Ho Yoon
Ho Young Son
Sung Woo Park
Yeon Ah Sung
Hong Sun Baek
Kyoung Soo Ha
Publication date
01-08-2014
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 4/2014
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0572-4

Other articles of this Issue 4/2014

Acta Diabetologica 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.